We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.25 | 9.00 | 9.50 | 9.25 | 9.25 | 9.25 | 59,297 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.67 | 16.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/3/2018 23:05 | How discouraging and disappointing is it to revisit this site only to find Bob is still shoring it up!!!! | owenmo | |
02/3/2018 11:49 | HERE IS AN INTERESTING ARTICLE that may eventually show SkinBio's creams prevent skin cancer. Common human skin bacteria could protect against cancer, say researchers Staphylococcus epidermidis may help to protect against skin cancer, and could lead to preventive treatments, scientists reveal | bobalot | |
02/3/2018 11:13 | We know the human trials are scheduled for Q3 but what do people see as the drivers of the share price before that? I realise when things are being announced in anticipation of the Q3 trials we should see the share price rise. | rafboy | |
02/3/2018 07:53 | Parob It's a level book for the first time since float so driven by buys and sells. Doesn't take much to move this now as we've seen this week. A few buys at bell and it will go again. Has the feel of n4p | shrewdmole | |
01/3/2018 18:53 | Decent volume today. Hasn't looked this good for months! This should build nicely leading up to the trials. | parob | |
01/3/2018 14:34 | A guy last week was primed to buy in heavily in the event of 2.5p. price shift (South). Well as of now we've got our 2.5p. only the wrong way for our would-be buyer. And so as and when this thing hits £1. buying to-day, he'd hold 50% less than last week's wished-for purchase; then of course half-a-loaf and all of that! Should have bought at 7.5 is the point I made at the time. | owenmo | |
01/3/2018 14:26 | New Interview on Directors Talk today: INTERVIEW: SkinBioTherapeutics Plc Positive Progress since October Posted by: giles.arbor 1st March 2018 SkinBioTherapeutics Plc (LON:SBTX) CEO Dr. Cath O’Neill talks to DirectorsTalk about the progress made since FY results in October 17. Cath provides us with an update, reminds us what SkinBioTherapeutics does and how its SkinBiotix® technology works, areas of skin health focused on, the significance of the successful scale-up and formulation, next milestones, other programmes and getting to market and progress on possible commercial partners. | parob | |
01/3/2018 14:25 | Looking good, breaking out of the down trend. | matt123d | |
01/3/2018 14:19 | Shrewdmole, very happy for you to be correct. Nice rise today. | rafboy | |
01/3/2018 14:17 | Who would have thought my skinbio shares would be my safe harbour today :) | rathean | |
01/3/2018 13:57 | It is worth noting that the three products can be offered either as a cream, gel or lotion which means the product can have more applications and is therefore more versatile and that equates to a wider audience of end users and higher revenues. | bobalot | |
01/3/2018 11:35 | Raf Tbh and it's far from a ramp I think if the human trials are successful ta worth way more than £30m ish. I jus think we could get a surprise whereby a company like johnson and johnson license a product and take it through the funding for the trials. Time will tell but it's very clever how soh has got partners to fund 500k plus on certain deals and further r and d.... | shrewdmole | |
01/3/2018 11:26 | Shrewdmole, I think you could be quite correct. Now is probably a great time to add before the human trials in Q3. Once these are announced the price will rise in anticipation. I am working on a conservative 30p by year end. | rafboy | |
01/3/2018 10:04 | My reasoning behind adding here is 2 fold. First we seem to have an orderly book for the first time since the listing. And secondly I believe that the in specie divi of Sbtx shares by Opti will be accompanied by a major step change Rns for Sbtx. Eg successful human trials and or commercial agreement. The fact they've scaled up test production and identified dosage and re application intervals says to me they are about there. Knowing how Opti have managed to get partners to fund further trials and r and d the human trial may have gone back slightly as it will come AFTER a commercial agreement and therefor get the partner I pay for those trials?!?! Just my thoughts on a snowy day! | shrewdmole | |
01/3/2018 08:28 | Well I've put my money where my mouth is so added 85k. | shrewdmole | |
28/2/2018 13:28 | Agreed Shrewdmole. | elrico | |
28/2/2018 13:12 | Personally I think this has been derisked more than people think and if you do the dd the info is out there. Sub 10p is a bargain IMHO. S | shrewdmole | |
28/2/2018 11:04 | ODR - prob good average point, accumulation mode, if you will on weakness. Some PI's don't have the nerve for it, instead preference is to buy into a rising SP, which I find odd because this obviously reduces the gains - least that is my logic. | elrico | |
28/2/2018 09:41 | Took advantage with another 41k. | onedayrodders | |
28/2/2018 09:28 | Look how quickly they run the share price down on far less volume. Don't you just love AIM. | onedayrodders | |
27/2/2018 16:18 | An excellent interview with Dr. Cath who says some very interesting things about probiotics in the skin care industry. SkinBioTherapeutics 'making very good headway' in development of three key programmes 16:02 26 Feb 2018 | bobalot | |
27/2/2018 14:49 | https://www.director | elrico |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions